-
October 2013 NuvaRing Label Change: Warnings And Precautions Section Sets Forth Two Competing Medical Studies About Side Effects
In Addition, The New Package Insert No Longer States It Is Unknown If NuvaRing Has A Different Blood Clot (VTE) Risk Than Some Birth Control Pills (Posted by Tom Lamb at DrugInjuryWatch.com) On October…
-
Is Plavix-Related Hemophilia Side Effect Significant Enough For Label Change In Europe But Not In U.S.
Sanofi Has Sent Out "Dear Doctor" Letters About The Association Of Plavix (Clopidogrel) Acquired Hemophilia There — Why Not Here, Too (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: This label revision regarding hemophilia…
-
Pradaxa Adverse Drug Events (ADEs) Result In Death More Often Than Other Anticoagulants / Blood Thinners ADE Reports
Again In 2012, Pradaxa (Dabigatran) Had Dubious Distinction Of Being Ranked First For Direct FDA Reports Of Adverse Events (Posted by Tom Lamb at DrugInjuryWatch.com) The October 2013 edition of ISMP QuarterWatch, Data from 2012…
-
Omontys-Related Adverse Reactions And Deaths Update: Are There More Cases Than Initially Disclosed
FDA Adverse Event Report For Omontys Reveals Affymax And Takeda May Have Downplayed Magnitude Of Problems (Posted by Tom Lamb at DrugInjuryWatch.com) When the dialysis – anemia medication Omontys was recalled in February 2013 it…
-
The Widespread “Off-Label” Use Of Medtronic Infuse Bone Graft And Associated Reports Of Adverse Events Involving Serious Injury
Up To 85% Of The Times This Infuse Device / System "Hybrid" Product Is Used By Surgeons, It Is For Some Surgery Type Not Approved By The FDA (Posted by Tom Lamb at DrugInjuryWatch.com) An April 2013…
